Patheon, a drug development and delivery solutions provider, is investing $45 million at key sites across its global network to meet growing customer demand for expanded service capabilities.
“As outsourcing of Pharma development and manufacturing services continues to grow, our customers will need even more advanced technologies and customized solutions to meet their business needs,” said Michel Lagarde, President of Patheon.
He added: “With the increasing marketplace pressures, pharma companies are looking to build more reliable, flexible and cost-efficient supply chains.”
The company’s South Carolina site – which it recently acquired from Roche – will be adding commercial spray drying capabilities, complementing the existing development capabilities available at the company’s low-solubility center of excellence in Bend, Oregon.
Patheon has invested in a new commercial sterile product manufacturing facility in its Monza, Italy site.
The facility will house three, 40 sq M lyophilizers with associated eight-headed integrated filling equipment for both lyo and liquid formulations for small and large molecules in a range of vial specifications.
Patheon also plans to expand its sterile product Pharmaceutical Development Services at the Monza facility.
Patheon will also expand its packaging and serialisation capabilities at its Greenville, NC site.
The investment follows the recent announcement that Patheon had been acquired by Thermo Fisher.